NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
80.96
+2.26 (+2.87%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close78.70
Open80.64
Bid81.09 x 2200
Ask81.16 x 1300
Day's Range80.25 - 81.00
52 Week Range72.30 - 94.19
Volume3,036,406
Avg. Volume1,727,026
Market Cap207.579B
Beta0.86
PE Ratio (TTM)23.73
EPS (TTM)3.41
Earnings DateN/A
Forward Dividend & Yield2.98 (3.85%)
Ex-Dividend Date2018-03-06
1y Target Est88.16
Trade prices are not sourced from all markets
  • Novartis CEO Says It's `Prudent' to Pull Back From Further Price Increases
    Bloomberg Videoyesterday

    Novartis CEO Says It's `Prudent' to Pull Back From Further Price Increases

    Jul.18 -- Novartis AG Chief Executive Officer Vas Narasimhan talks about U.S. drug pricing, government health-care policy and plans to spin off the Swiss drugmaker's Alcon eye-care unit. He speaks from Basel, Switzerland, on "Bloomberg Daybreak: Europe" after profit beat estimates in the second quarter, allowing Novartis to reiterate its full-year forecast.

  • Bloomberg2 hours ago

    Novartis to Pay as Much as $1 Billion for Rights to Skin Drug

    Novartis AG agreed to buy the rights to a skin-disease drug from developers Galapagos NV and MorphoSys AG in a deal that could reach $1 billion as Chief Executive Officer Vas Narasimhan centers the Swiss drugmaker on developing innovative prescription medicines. Novartis will pay 95 million euros ($111 million) upfront and later payments of up to 850 million euros based on the drug reaching certain regulatory, commercial and sales goals, MorphoSys said in a statement Thursday. The payments will be split 50-50 between Mechelen, Belgium-based Galapagos and Planegg, Germany-based MorphoSys.

  • Reuters2 hours ago

    Novartis to pay 95 mln euros to Galapagos, MorphoSys for skin drug

    Novartis said on Thursday it will pay 95 million euros to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its ...

  • The Wall Street Journal8 hours ago

    [$$] Novartis Won’t Raise U.S. Drug Prices This Year

    Novartis AG won’t increase its U.S. drug prices for the rest of 2018, the Switzerland-based drugmaker said Wednesday, days after Pfizer Inc. took a similar step following criticism from President Donald Trump. In an interview, Novartis Chief Executive Vas Narasimhan said the company would evaluate its strategy for 2019 when it has more clarity on the pricing environment. Last week, Pfizer said it would defer some recent drug-price increases, reversing course after Mr. Trump criticized the company for its plans to raise the prices of more than 40 drugs.

  • Novartis Q2 Earnings Miss, Sales Top on Cosentyx, Entresto
    Zacks12 hours ago

    Novartis Q2 Earnings Miss, Sales Top on Cosentyx, Entresto

    Novartis (NVS) misses on Q2 earnings but beats sales on the back of continued momentum from Cosentyx and Entresto. Oncology franchise also exhibits strong growth.

  • TheStreet.com13 hours ago

    5 Big Biotech Stories to Watch

    President Trump's attack on large pharma companies over drug prices might have grabbed headlines recently, but that shouldn't distract from the firms and drugs that have been driving change and innovation in the biotech industry. Here's a rundown of some of the news from small to large companies in the past few weeks that could have a big impact on the biotechnology and pharmaceutical sectors. 1. Biogen's Alzheimer's drug trial results show promise Curing Alzheimer's disease has frustrated the healthcare industry for years after numerous failed attempts have been made to find a treatment, but Biogen Inc.

  • Reuters16 hours ago

    Novartis hints at 2018 outlook hike despite drug price freeze

    Novartis (NOVN.S) may ratchet up its 2018 sales outlook, its finance chief said on Wednesday, despite halting planned U.S. drug price hikes amid pressure on the industry from President Donald Trump's administration over the high cost of medicines. Shares in the Swiss drugmaker, whose decision to freeze prices this year in the world's largest drug market was mirrored by Pfizer (PFE.N), closed 2.5 percent higher in Zurich after the firm beat forecasts with second-quarter results.

  • Novartis hints at 2018 outlook hike despite drug price freeze
    Reuters16 hours ago

    Novartis hints at 2018 outlook hike despite drug price freeze

    Novartis (NOVN.S) may ratchet up its 2018 sales outlook, its finance chief said on Wednesday, despite halting planned U.S. drug price hikes amid pressure on the industry from President Donald Trump's administration over the high cost of medicines. Shares in the Swiss drugmaker, whose decision to freeze prices this year in the world's largest drug market was mirrored by Pfizer (PFE.N), closed 2.5 percent higher in Zurich after the firm beat forecasts with second-quarter results.

  • Barrons.com16 hours ago

    Novartis Earnings: 'A Focused Company Wins,' Says CEO

    Shares of Novartis (NVS) are climbing on Wednesday after the company reported second-quarter earnings. For the full year, Novartis reaffirmed guidance, saying it expects revenue percentage growth of low- to mid-single digits. The report comes after a number of changes at Novartis, including plans to spin off the Alcon eye-care business, the purchase of gene-therapy company AveXis, and the divestiture of its stake in a consumer health-care business joint venture with GlaxoSmithKline (GSK).

  • Novartis’s Business Segments in Q2 2018
    Market Realist17 hours ago

    Novartis’s Business Segments in Q2 2018

    As we’ve already seen, Novartis (NVS) surpassed Wall Street analysts’ estimates for Q2 2018 and reported revenues of $13.2 billion. That’s a 7% growth YoY (year-over-year) compared to $12.2 billion in Q2 2017. Novartis AG is the holding company providing healthcare solutions. Its business is classified into the following three business segments: Innovative Medicines: prescription medicines Sandoz: generics Alcon: eye care

  • Novartis AG (NVS) Q2 2018 Earnings Conference Call Transcript
    Motley Fool17 hours ago

    Novartis AG (NVS) Q2 2018 Earnings Conference Call Transcript

    NVS earnings call for the period ending June 30, 2018.

  • Novartis Reports Growth in Q2 2018 Earnings
    Market Realist19 hours ago

    Novartis Reports Growth in Q2 2018 Earnings

    Novartis (NVS) released its Q2 2018 earnings on July 18 and surpassed Wall Street analysts’ estimates for revenues and EPS. It reported revenues of $13.2 billion and EPS of $1.29, which compares to the estimated EPS of $1.28 on revenues of $13 billion.

  • Benzinga20 hours ago

    Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on July 17) Avid Bioservices Inc (NASDAQ: CDMO )( reversed to a profit ...

  • Reuters22 hours ago

    Novartis joins Pfizer in halting U.S. drug price hikes

    Novartis expects to hit the top of its 2018 sales guidance after a strong second quarter, the CEO said, despite joining Pfizer in freezing its U.S. drug prices for the rest of the year following pressure from President Donald Trump. Chief Executive Vas Narasimhan said Novartis would likely easily achieve mid-single digit percentage sales growth for 2018, on rising demand for psoriasis-and-arthritis drug Cosentyx and robust sales of heart-failure medicine Entresto. "We would expect to see, assuming continued momentum like we're seeing now, to be at the high end of that range," Narasimhan said, adding that this would come without price hikes as Novartis keeps the lid on medicine costs under pressure from U.S. lawmakers and Trump.

  • Associated Press23 hours ago

    Novartis: 2Q Earnings Snapshot

    The Basel, Switzerland-based company said it had net income of $3.31 per share. Earnings, adjusted for non-recurring gains, came to $1.26 per share. The results fell short of Wall Street expectations. ...

  • Novartis CEO Says It's `Prudent' to Pull Back From Further Price Increases
    Bloombergyesterday

    Novartis CEO Says It's `Prudent' to Pull Back From Further Price Increases

    Novartis AG Chief Executive Officer Vas Narasimhan talks about U.S. drug pricing, government health-care policy and plans to spin off the Swiss drugmaker's Alcon eye-care unit. He speaks from Basel, Switzerland, ...

  • Associated Pressyesterday

    Swiss drugs giant Novartis says profit up as spinoff looms

    GENEVA (AP) — Novartis says net profit rose 3 percent in the second quarter amid strong growth for some of its top products, as the Swiss pharmaceuticals giant moves to spin off its Alcon eye-care business.

  • Novartis Joins Pfizer in Holding Line on Drug Prices in U.S.
    Bloombergyesterday

    Novartis Joins Pfizer in Holding Line on Drug Prices in U.S.

    Swiss drugmaker Novartis AG is holding the line on U.S. prices this year as an attack from President Donald Trump led rival Pfizer Inc. to delay planned increases for some medicines. Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday.

  • Novartis CEO Says Drugmaker Won't Raise U.S. Prices This Year
    Bloombergyesterday

    Novartis CEO Says Drugmaker Won't Raise U.S. Prices This Year

    Swiss drugmaker Novartis AG is holding the line on prices in the U.S. this year, following a move by rival Pfizer Inc. to delay planned increases for some medicines after President Donald Trump launched an attack on the U.S. pharma giant. Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday with journalists. Pfizer last week agreed to defer planned price increases for certain drugs a day after Trump targeted Pfizer over reported plans to implement a series of price increases, criticizing the move on Twitter and briefly rattling its shares.